A multicenter retrospective study comparing the therapeutic effects and relapse rates of secukinumab on plaque psoriasis of varying severity - 14/06/26
Doi : 10.1016/j.jaad.2026.01.110
Bin Wang, MM a, b, Suchun Hou, MD a, b, Lan-Tu-Ya Wu, MS c, Xiaojing Kang, MD d, Bin Yang, MD e, Hongzhong Jin, MD f, Huiwei Wang, MS b, Wei Li, MD g, Fuqiu Li, MD h, Xiaoming Liu, MD i, ⁎ 
a Department of Dermatology, Shenzhen University General Hospital, Shenzhen, China
b Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
c School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China
d Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China
e Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China
f Department of Dermatology, Peking Union Medical College Hospital, Beijing, China
g Department of Dermatology & Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
h Department of Dermatology, The Second Norman Bethune Hospital of Jilin University, Jilin University, Changchun, Jilin Province, China
i Nanshan Hospital of Shenzhen University Health Science Center, Shenzhen, China
∗ Correspondence to: Xiaoming Liu, MD, Department of Dermatology, Shenzhen Nanshan People's Hospital, No. 89 Taoyuan Rd, Nanshan District, Shenzhen, Guangdong, China 518000 Department of Dermatology Shenzhen Nanshan People's Hospital No. 89 Taoyuan Rd Nanshan District Shenzhen Guangdong 518000 China
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Sunday 14 June 2026
Key words : plaque psoriasis, relapse rates, secukinumab, severity, therapeutic effects
Le texte complet de cet article est disponible en PDF.
| Dr Hou is co-first authors. |
|
| Funding sources: Supported by Sanming Project of Medicine in Shenzhen (No. SZSM202103014 ). |
|
| Patient consent: The authors certify that they have obtained appropriate patient consent for the publication of the case details and clinical information, on the understanding that it contains no photographs or identifiable personal information. |
|
| IRB approval status: Not applicable. |
© 2026
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?